Cargando…

COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group

In the era of novel coronavirus epidemics, vaccines against coronavirus disease 2019 (COVID-19) have been recognized as the most effective public health interventions to control the pandemic. An adverse event following immunization (AEFI) is defined as any untoward occurrence following immunization,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Mi-Ae, Lee, Yong Won, Kim, So Ri, Kim, Joo-Hee, Min, Taek ki, Park, Hae-Sim, Shin, Meeyong, Ye, Young-Min, Lee, Sooyoung, Lee, Jeongmin, Choi, Jeong-Hee, Jang, Gwang Cheon, Chang, Yoon-Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255352/
https://www.ncbi.nlm.nih.gov/pubmed/34212542
http://dx.doi.org/10.4168/aair.2021.13.4.526
_version_ 1783717885120610304
author Kim, Mi-Ae
Lee, Yong Won
Kim, So Ri
Kim, Joo-Hee
Min, Taek ki
Park, Hae-Sim
Shin, Meeyong
Ye, Young-Min
Lee, Sooyoung
Lee, Jeongmin
Choi, Jeong-Hee
Jang, Gwang Cheon
Chang, Yoon-Seok
author_facet Kim, Mi-Ae
Lee, Yong Won
Kim, So Ri
Kim, Joo-Hee
Min, Taek ki
Park, Hae-Sim
Shin, Meeyong
Ye, Young-Min
Lee, Sooyoung
Lee, Jeongmin
Choi, Jeong-Hee
Jang, Gwang Cheon
Chang, Yoon-Seok
author_sort Kim, Mi-Ae
collection PubMed
description In the era of novel coronavirus epidemics, vaccines against coronavirus disease 2019 (COVID-19) have been recognized as the most effective public health interventions to control the pandemic. An adverse event following immunization (AEFI) is defined as any untoward occurrence following immunization, and the majority of AEFIs are caused by protective immune responses stimulated by vaccines. Most of the reported AEFIs are not serious, and many are not immunologically mediated or even reproducible on re-exposure. However, uncommon severe allergic adverse reactions, such as anaphylaxis or other allergic reactions, can occur after vaccinations. Confirmed allergic reactions to vaccines may be caused by residual non-human protein, preservatives, or stabilizers in the vaccine formulation (also known as excipients). There are 2 main potential allergenic/immunogenic excipients in COVID-19 vaccines, polyethylene glycol (PEG) and polysorbate 80. PEG, also known as macrogol, is an ingredient in various laxatives and injectable formulations, such as depot steroids. Polysorbate 80 is present in various medical products, creams, ointments, lotions, and medication tablets. Contraindications to the administration of COVID-19 vaccines include a previous history of severe allergic reactions to the first dose of COVID-19 vaccine or proven hypersensitivity to a vaccine component, such as PEG or polysorbate 80. Anaphylaxis or other allergic reactions following immunization can cause fear and loss of confidence in the safety of vaccines among the public. A better understanding of these events is thought to help alleviate concerns about the current COVID-19 vaccines and provide reassurance to the general population by analyzing the exact incidence of anaphylaxis and potential risk factors. COVID-19 vaccine-associated anaphylaxis could be prevented and managed by risk stratification based on our local and global experience.
format Online
Article
Text
id pubmed-8255352
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease
record_format MEDLINE/PubMed
spelling pubmed-82553522021-07-06 COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group Kim, Mi-Ae Lee, Yong Won Kim, So Ri Kim, Joo-Hee Min, Taek ki Park, Hae-Sim Shin, Meeyong Ye, Young-Min Lee, Sooyoung Lee, Jeongmin Choi, Jeong-Hee Jang, Gwang Cheon Chang, Yoon-Seok Allergy Asthma Immunol Res Review In the era of novel coronavirus epidemics, vaccines against coronavirus disease 2019 (COVID-19) have been recognized as the most effective public health interventions to control the pandemic. An adverse event following immunization (AEFI) is defined as any untoward occurrence following immunization, and the majority of AEFIs are caused by protective immune responses stimulated by vaccines. Most of the reported AEFIs are not serious, and many are not immunologically mediated or even reproducible on re-exposure. However, uncommon severe allergic adverse reactions, such as anaphylaxis or other allergic reactions, can occur after vaccinations. Confirmed allergic reactions to vaccines may be caused by residual non-human protein, preservatives, or stabilizers in the vaccine formulation (also known as excipients). There are 2 main potential allergenic/immunogenic excipients in COVID-19 vaccines, polyethylene glycol (PEG) and polysorbate 80. PEG, also known as macrogol, is an ingredient in various laxatives and injectable formulations, such as depot steroids. Polysorbate 80 is present in various medical products, creams, ointments, lotions, and medication tablets. Contraindications to the administration of COVID-19 vaccines include a previous history of severe allergic reactions to the first dose of COVID-19 vaccine or proven hypersensitivity to a vaccine component, such as PEG or polysorbate 80. Anaphylaxis or other allergic reactions following immunization can cause fear and loss of confidence in the safety of vaccines among the public. A better understanding of these events is thought to help alleviate concerns about the current COVID-19 vaccines and provide reassurance to the general population by analyzing the exact incidence of anaphylaxis and potential risk factors. COVID-19 vaccine-associated anaphylaxis could be prevented and managed by risk stratification based on our local and global experience. The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2021-06-21 /pmc/articles/PMC8255352/ /pubmed/34212542 http://dx.doi.org/10.4168/aair.2021.13.4.526 Text en Copyright © 2021 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Kim, Mi-Ae
Lee, Yong Won
Kim, So Ri
Kim, Joo-Hee
Min, Taek ki
Park, Hae-Sim
Shin, Meeyong
Ye, Young-Min
Lee, Sooyoung
Lee, Jeongmin
Choi, Jeong-Hee
Jang, Gwang Cheon
Chang, Yoon-Seok
COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group
title COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group
title_full COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group
title_fullStr COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group
title_full_unstemmed COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group
title_short COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group
title_sort covid-19 vaccine-associated anaphylaxis and allergic reactions: consensus statements of the kaaaci urticaria/angioedema/anaphylaxis working group
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255352/
https://www.ncbi.nlm.nih.gov/pubmed/34212542
http://dx.doi.org/10.4168/aair.2021.13.4.526
work_keys_str_mv AT kimmiae covid19vaccineassociatedanaphylaxisandallergicreactionsconsensusstatementsofthekaaaciurticariaangioedemaanaphylaxisworkinggroup
AT leeyongwon covid19vaccineassociatedanaphylaxisandallergicreactionsconsensusstatementsofthekaaaciurticariaangioedemaanaphylaxisworkinggroup
AT kimsori covid19vaccineassociatedanaphylaxisandallergicreactionsconsensusstatementsofthekaaaciurticariaangioedemaanaphylaxisworkinggroup
AT kimjoohee covid19vaccineassociatedanaphylaxisandallergicreactionsconsensusstatementsofthekaaaciurticariaangioedemaanaphylaxisworkinggroup
AT mintaekki covid19vaccineassociatedanaphylaxisandallergicreactionsconsensusstatementsofthekaaaciurticariaangioedemaanaphylaxisworkinggroup
AT parkhaesim covid19vaccineassociatedanaphylaxisandallergicreactionsconsensusstatementsofthekaaaciurticariaangioedemaanaphylaxisworkinggroup
AT shinmeeyong covid19vaccineassociatedanaphylaxisandallergicreactionsconsensusstatementsofthekaaaciurticariaangioedemaanaphylaxisworkinggroup
AT yeyoungmin covid19vaccineassociatedanaphylaxisandallergicreactionsconsensusstatementsofthekaaaciurticariaangioedemaanaphylaxisworkinggroup
AT leesooyoung covid19vaccineassociatedanaphylaxisandallergicreactionsconsensusstatementsofthekaaaciurticariaangioedemaanaphylaxisworkinggroup
AT leejeongmin covid19vaccineassociatedanaphylaxisandallergicreactionsconsensusstatementsofthekaaaciurticariaangioedemaanaphylaxisworkinggroup
AT choijeonghee covid19vaccineassociatedanaphylaxisandallergicreactionsconsensusstatementsofthekaaaciurticariaangioedemaanaphylaxisworkinggroup
AT janggwangcheon covid19vaccineassociatedanaphylaxisandallergicreactionsconsensusstatementsofthekaaaciurticariaangioedemaanaphylaxisworkinggroup
AT changyoonseok covid19vaccineassociatedanaphylaxisandallergicreactionsconsensusstatementsofthekaaaciurticariaangioedemaanaphylaxisworkinggroup